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Objectives. We tested the hypothesis that nitric oxide (NO)
cyclic guanosine 5*-monophosphate (GMP) signaling is deficient
in pressure overload hypertrophy due to ascending aortic stenosis,
and that long-term L-arginine treatment will increase cardiac
cyclic GMP production and modify left ventricular (LV) pressure
overload hypertrophy and beta-adrenergic contractile response.
Background. Nitric oxide cyclic GMP signaling is postulated to
depress vascular growth, but its effects on cardiac hypertrophic
growth are controversial.
Methods. Forty control rats and 40 rats with aortic stenosis left
ventricular hypertrophy ([LVH] group) were randomized to re-
ceive either L-arginine (0.40 g/kg/day) or no drug for 6 weeks.
Results. The dose of L-arginine did not alter systemic blood
pressure. Animals with LVH had similar LV constitutive nitric
oxide synthase (cNOS) mRNA and protein levels, and LV cyclic
GMP levels as compared with age-matched controls. In rats with
LVH L-arginine treatment led to a 35% increase in cNOS protein
levels (p 5 0.09 vs untreated animals with LVH) and a 1.7-fold
increase in LV cyclic GMP levels (p < 0.05 vs untreated animals
with LVH). However, L-arginine treatment did not suppress LVH
in the animals with aortic stenosis. In contrast, in vivo LV systolic
pressure was depressed in L-arginine treated versus untreated
rats with LVH (163 6 16 vs 198 6 10 mm Hg, p < 0.05). In
addition, the contractile response to isoproterenol was blunted in
both isolated intact hearts and isolated myocytes from L-arginine
treated rats with LVH compared with untreated rats with LVH.
This effect was mediated by a blunted increase in peak systolic
intracellular calcium in response to beta-adrenergic stimulation.
Conclusions. Left ventricular hypertrophy due to chronic me-
chanical systolic pressure overload is not characterized by a
deficiency of LV cNOS and cyclic GMP levels. In rats with aortic
stenosis, L-arginine treatment increased cardiac levels of cyclic
GMP, but it did not modify cardiac mass in rats with aortic
stenosis. However, long-term stimulation of NO-cyclic GMP sig-
naling depressed in vivo LV systolic function in LVH rats and
markedly blunted the contractile response to beta-adrenergic
stimulation.
(J Am Coll Cardiol 1998;32:528–35)
©1998 by the American College of Cardiology
Long-term angiotensin-converting enzyme (ACE) inhibition
improves left ventricular (LV) function and attenuates pro-
gression of LV hypertrophy (LVH) (1–3). Several studies
suggest that part of the effects of long-term ACE inhibition are
related to an enhanced activation of the nitric oxide (NO)-
cyclic guanosine 59-monophosphate (GMP) pathway (4,5), but
the effects of this pathway on cardiac growth are unknown. It
has been demonstrated that acute stimulation of the NO-cyclic
GMP pathway directly depresses myocardial contractile per-
formance (6–8) and attenuates the contractile response to
beta-adrenergic stimulation (8–13). In addition, in vitro stud-
ies in vascular smooth muscle cells showed that the NO-cyclic
GMP pathway modifies cell growth (14,15).
Recent studies, which agree with this concept, have postu-
lated that deficient NO-cyclic GMP production is a fundamen-
tal pathophysiologic mechanism in genetic models of hyper-
tension (16–19), such as the spontaneously hypertensive rat
model (16,18) or essential hypertension in humans (19). Mat-
suoka et al. (18) reported that hypertensive rats are character-
ized by decreased cardiac cyclic GMP content related to NO
production, which could be corrected by long-term L-arginine
treatment. They observed that normalization of cardiac cyclic
GMP content attenuated progression of cardiac hypertrophy.
It is unclear whether these provocative observations are rele-
vant to chronic hypertrophy due to mechanical overload such
as aortic stenosis. Accordingly, we tested the hypothesis that
LVH in rats with ascending aortic stenosis is characterized by
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a deficiency in cardiac cyclic GMP production. Second, we
predicted that L-arginine treatment would increase NO-
mediated cyclic GMP generation and directly suppress hyper-
trophic growth in vivo. Third, we postulated that augmented
NO-cyclic GMP signaling by long-term L-arginine will modify
both in vivo LV systolic performance and the contractile
response to beta-adrenergic stimulation.
Methods
L-arginine treatment protocol. Weanling male Wistar rats
(3 to 4 weeks old, 75 to 100 g, Charles River Breeding
Laboratories, Wilmington, Delaware) were banded by placing
a stainless steel clip of 0.6-mm internal diameter on the
ascending aorta via a thoracic incision as previously described
(2,21). Age-matched animals served as a control group. Rats
were fed normal rat chow and water ad libitum.
One week after surgery, rats with aortic stenosis and
age-matched controls were randomized to receive either
L-arginine in drinking water (0.40 g/kg/day) or no treatment.
The dose of L-arginine was chosen on the basis of prior studies
in the literature demonstrating that the dose is sufficient to
increase cardiac cyclic GMP content (18,20), and on the basis
of a pilot-dosing experiment, in which this dose did not affect
systemic tail-cuff blood pressure in control animals (n 5 6)
over a 1-week period. There were four groups in the study:
L-arginine treated rats with aortic stenosis (n 5 14), untreated
rats with aortic stenosis (n 5 14) and age-matched controls
receiving L-arginine treatment (n 5 20) and not receiving
L-arginine (n 5 20). This randomized treatment continued for
6 weeks.
In vivo measurements. Animals were monitored daily.
Body weight was measured weekly. In vivo tail-cuff systemic
blood pressure was measured during weeks 4 to 6 of treatment.
At the end of the treatment period, in vivo LV pressure
measurements were performed before sacrifice as previously
described (2). After the animals were sacrificed, tibia, lungs
and kidneys were stored at 280°C for further analysis. Tibial
length was used as an index of body growth independent of
body mass.
Effect of isoproterenol in isolated perfused hearts. Isolated
hearts were evaluated using the isovolumic buffer-perfused rat
heart preparation with constant coronary flow as described
elsewhere (2). All hearts were allowed to stabilize for 15
minutes. Left ventricular diastolic pressure–volume curves
were generated as previously described (2). Then, hearts from
each group were perfused with isoproterenol at doses of 10210,
1029, 1028 and 1027 mol/L, each for 5 min. At the end of the
experiment, hearts were removed and dissected within 15 s,
and the left and right ventricles were quickly weighed and
frozen in liquid nitrogen for further analysis.
Effects of isoproterenol in isolated myocytes. At the end of
treatment period, additional rats (two to three per group) were
used for isolated myocyte experiments. Left ventricular myo-
cytes were prepared as previously described (21,22). Intracel-
lular calcium [Ca21]i was measured with the Ca
21-sensitive
fluorescence indicator indol-AM (Molecular Probes Inc, Eu-
gene, Oregon) as described elsewhere (21,22). To investigate
the response to beta-adrenergic stimulation after chronic
L-arginine treatment, isolated myocytes were superfused with
oxygenated HEPES-buffered solution (pH 5 7.40, 37°C) and
paced at 0.5 Hz. After recording baseline data, the cells were
superfused with isoproterenol at concentrations of 10210, 1029
and 1028 mol/L. Simultaneous measurements of cell shorten-
ing and [Ca21]i were measured after 5 min of superfusion at
each concentration.
Measurements of tissue cyclic GMP levels. The frozen
tissues from the left ventricle and kidney were rapidly weighed
and pulverized under liquid nitrogen. A part of the frozen
powder was taken to quantitate the ratio of frozen to dry
weight. The remaining powder was homogenized in cold 6%
trichloracetic acid to obtain a final 10% homogenate. The
homogenate was centrifuged for 20 min at 10,000 rpm and the
supernatant was recovered and washed 4 times with 5 volumes
of water-saturated ethyl ether. Final aqueous extract was dried
at 60°C under a stream of nitrogen. Left ventricular cyclic
GMP levels were determined by enzymatic assay (Amersham,
Life Science, UK) and expressed as picomolar per gram dry
weight.
Ribonuclease protection assay of nitric oxide synthase
mRNA. Total RNA was isolated from frozen LV tissue by the
guanidinium/cesium chloride method. Left ventricular tissue
was analyzed from four untreated control and rats with aortic
stenosis. Labeled riboprobes were generated using MAXIcript
In Vitro Transcription kit (Ambion, Austin, Texas) and 32P-
alpha-UTP. Labeled RNA was separated from unincorporated
nucleotides by spin chromatography (Chromaspin-100, Clon-
tech, Palo Alto, California). The constitutive nitric oxide
synthase (cNOS) probe was linearized with XhoI and yielded a
303 base-pair (bp) fragment (7). The rat beta-actin probe was
derived from clone pSKrBac and yielded a 150 bp fragment
after linearization with XhoI. Fifty micrograms of total RNA
was hybridized to 1 3 105 cpm of cNOS RNA and 1 3 104 cpm
of beta-actin cRNA and then treated with RNase A/RNase T1
(Ambion). After RNase inactivation and precipitation of the
protected fragments, the samples were separated on a 5%
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BW 5 body weight
[Ca21]i 5 intracellular calcium
GMP 5 guanosine 59-monophosphate
LV 5 left ventricular
LV devP 5 left ventricular developed pressure
LV dP/dt 5 first derivative of left ventricular pressure
LVEDP 5 left ventricular end-diastolic pressure
LVH 5 left ventricular hypertrophy
LVSP 5 left ventricular systolic pressure
NO 5 nitric oxide
NOS 5 nitric oxide synthase
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polyacrylamide gel. The gel was exposed to autoradiographic
film (Kodak MR) overnight, and hybridization signals were
quantified with Image Quant Software (Molecular Dynamics,
Sunnyvale, California). Constitutive nitric oxide synthase levels
were normalized to beta-actin mRNA levels.
Western blot analysis of nitric oxide synthase proteins.
Left ventricular tissue was rapidly homogenized in 5 volumes
of a lysis buffer containing 10 mmol/L Tris HCl, 1 mmol/L
orthodium vanadate and 1% SDS. Left ventricular tissue was
analyzed from 11 untreated control rats, 9 L-arginine treated
control rats and 15 L-arginine treated and untreated rats with
aortic stenosis. Homogenized samples were microwaved for
15 s and centrifuged for 20 min at 10,000 rpm. Supernatant was
recovered and proteins were quantified using Lowry assay
(Sigma Chemical, St. Louis, Missouri). One hundred micro-
grams of denaturated protein per lane were loaded and
separated on a 10% SDS-PAGE gel. Random samples from
each group were loaded into each gel. Eight microliters of
human aortic endothelial cell proteins (concentration 1 mg/ml)
were loaded into each gel and served as a positive control.
Separated proteins were transferred to a nitrocellulose mem-
brane. Membranes were exposed to constitutive or inducible
NOS specific monoclonal antibody (both at 1:800, Transduc-
tion Laboratories, Lexington, Kentucky) for 1 h followed by six
washes and incubation with a goat antimouse secondary anti-
body coupled to peroxidase activity (1:5,000). The membranes
were incubated with chemiluminiscence detection reagent
(Amersham, Life Science) and exposed to Kodak film for 30 to
40 s.
Statistical analysis. All data are expressed as mean 6
SEM. Student unpaired t test was used where appropriate.
Comparison between groups was performed by analysis of
variance (ANOVA) comparison or ANOVA for repeated
measures, where appropriate, followed by Fisher’s exact test
for post hoc analyses. A p value ,0.05 was considered signif-
icant.
Results
Effect of L-arginine on left ventricular hypertrophy. In
both the control rats and the rats with aortic stenosis,
L-arginine had no effect on body weight and on tibial length, an
index of growth independent from body fat, muscle or fluid
homeostasis among the groups (Table 1). As shown in Table 1,
systolic tail-cuff blood pressure was slightly lower in untreated
rats with aortic stenosis compared with control rats. At the
dose used in this long-term trial, L-arginine had no effect on
systolic blood pressure in control rats or rats with aortic
stenosis. The effect of L-arginine on LV growth is shown in
Table 1. Left ventricular weight and LV/body weight ratio were
significantly greater in rats with aortic stenosis than in control
rats. However, LV weight was similar between L-arginine
treated rats and untreated rats with aortic stenosis.
In vivo left ventricular function. To assess the effect of
L-arginine on in vivo LV function, LV pressure was measured
in closed-chest animals before sacrifice (Figure 1). In control
rats, absolute LV systolic pressure (LVSP) and LV developed
pressure/g LV (LVdevP/g) were similar in L-arginine treated
and untreated rats (n 5 10 per group). In untreated rats with
Figure 1. Bar graph showing in vivo LVSP measurements. Upper left,
in vivo LVSP in control animals. Upper right, in vivo LVSP in rats with
aortic stenosis. Lower left, in vivo LV developed pressure/g
(LVdevP/g) in control rats. Lower right, In vivo LVdevP/g in rats with
aortic stenosis. C 5 control rats not receiving drugs; C-L-arg 5 control
rats treated with L-arginine; LVH 5 rats with aortic stenosis not
receiving drugs; LVH-L-arg: rats with aortic stenosis treated with
L-arginine.
Table 1. Left Ventricular Hypertrophy and Blood Pressure
Group
Body Wt
(g)
Tibial Lt
(mm)
LV Wt
(g)
LV Wt/Body Wt
(g/kg)
BP
(mm Hg)
C (n 5 10) 400.8 6 5.8 39.2 6 .4 .99 6 .04 2.53 6 .08 126 6 1
C-L-arg (n 5 10) 386.5 6 11.6 39.3 6 .4 1.01 6 .02 2.56 6 .09 132 6 5
LVH (n 5 10) 391.4 6 12.1 39.9 6 .3 1.61 6 .05* 4.01 6 .16* 109 6 6*
LVH-L-arg (n 5 11) 407.8 6 7.1 40.2 6 .4 1.70 6 .03* 4.02 6 .09* 110 6 5*
*p , 0.05 versus controls.
Body Wt 5 body weight; BP 5 systolic tail-cuff blood pressure; C 5 control untreated animals; C-L-arg 5 L-arginine
treated control animals; LV Wt 5 left ventricular weight; LVH 5 untreated aortic banded animals; LVH-L-arg 5
L-arginine treated animals with aortic stenosis; Tibial Lt 5 tibial length.
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aortic stenosis, in vivo LVSP and LVdevP/g were higher than
in control animals. However, both absolute LVSP and
LVdevP/g were significantly lower in L-arginine treated rats
(n 5 11) compared with untreated rats with aortic stenosis
(n 5 13). In addition, maximum and minimum first derivative
of LV pressure (LV dP/dt) tended to be lower in L-arginine
treated than in untreated rats with aortic stenosis (6,625 6
1,080 vs 8,196 6 438 mm Hg/s, p 5 0.13, and 5,857 6 964 vs
7,156 6 478 mm Hg/s, p 5 0.19, respectively).
In vivo LV end-diastolic pressure (LVEDP) was higher in
rats with aortic stenosis than in control rats (12.9 6 2.6 vs 6.5 6
1.0 mm Hg, p , 0.01). However, LVEDP was similar in
animals with aortic stenosis with and without L-arginine
(14.8 6 1.8 vs 12.9 6 2.6 mm Hg; p 5 NS).
Contractile response to isoproterenol in isolated hearts.
Isolated heart studies were used to examine the contractile
response to beta-adrenergic stimulation in L-arginine treated
and untreated rats. Hearts in all groups were perfused at a
comparable flow rate per gram ('18 ml/min/g) and at a similar
heart rate ('280 beats/min). As expected, there was an upward
and leftward shift of the LV diastolic pressure–volume relation
in rats with aortic stenosis compared with control rats. How-
ever, the LV diastolic pressure–volume relation showed no
difference in LV diastolic chamber distensibility in the pres-
ence or absence of L-arginine treatment (data not shown).
Then, LV volume was adjusted to achieve a comparable level
of LVEDP in all groups (11 mm Hg). At this level of LVEDP,
LV volume was similar between treated and untreated control
rats (0.22 6 0.04 vs 0.19 6 0.02 ml) and rats with aortic stenosis
(0.14 6 0.02 vs 0.13 6 0.02 ml). Under these perfusion
conditions, LV systolic pressure was similar in L-arginine
treated and untreated control rats (124 6 10 vs 110 6
5 mm Hg), and in L-arginine treated and untreated rats with
aortic stenosis (161 6 13 vs 151 6 14 mm Hg). The dose
response of coronary perfusion pressure and heart rate to
isoproterenol was similar between treated and untreated con-
trol rats and rats with aortic stenosis (data not shown). There
was no significant change in LVEDP during isoproterenol
infusion in any group. As shown in Figure 2, in control animals
(left panel), isoproterenol caused a similar dose-dependent
increase in LV systolic pressure in hearts from both L-arginine
treated and untreated animals (p , 0.001 vs baseline). Hearts
from untreated rats with aortic stenosis also demonstrated a
significant dose-dependent increase in LVSP (Fig. 2, right
panel, p , 0.001 vs baseline), whereas there was no increase in
LVSP in hearts from L-arginine treated rats with aortic stenosis
(p 5 NS).
Response to isoproterenol in isolated myocytes: effect on
contractility and [Ca21]i. We then examined effects of iso-
proterenol on contractility of isolated myocytes. The baseline
function of LV myocytes from control and hypertrophied
hearts is shown in Table 2. Figure 3 shows the effects of
isoproterenol on myocyte shortening. Isoproterenol induced a
similar, dose-dependent increase in fractional shortening in
myocytes from treated and untreated control animals (p ,
0.001 vs baseline; Fig. 3, left panel). In hypertrophied myocytes
from animals with aortic stenosis, the relative increase in
fractional shortening (Fig. 3, right panel) was much higher in
hypertrophied myocytes from untreated rats with aortic steno-
sis than in myocytes from L-arginine treated rats with aortic
stenosis (p , 0.05 by ANOVA).
The dose-dependent effects of isoproterenol on systolic
[Ca21]i are shown in Figure 4. Isoproterenol induced a similar
increase in systolic [Ca21]i in control myocytes from L-arginine
treated and untreated rats (Fig. 4, left panel). In hypertrophied
myocytes, the relative increase in systolic [Ca21]i tended to be
lower in myocytes from L-arginine treated than in untreated
rats with aortic stenosis (p 5 0.08 by ANOVA; Fig. 4, right
Figure 2. Graph showing the contractile response to iso-
proterenol in isolated intact hearts from control animals
(left panel) and rats with aortic stenosis (right panel).
Abbreviations as in Figure 1.
Table 2. Baseline Characteristics of Isolated Myocytes
C
(n 5 9)
C-L-ARG
(N 5 8)
LVH
(n 5 9)
LVH-L-arg
(n 5 8)
Diastolic length
(mm)
122.6 6 4.1 125.1 6 4.5 151.1 6 5.1* 155.3 6 4.2*
Systolic shortening
(mm)
10.9 6 1.5 11.1 6 1.1 13.7 6 2.6 14.9 6 2.5
Fractional shortening
(%)
8.7 6 1.1 9.1 6 .8 8.8 6 .8 9.7 6 1.5
End-diastolic [Ca21]i
(nM)
79 6 13 76 6 14 78 6 17 99 6 117
Peak-systolic [Ca21]i
(nM)
534 6 137 542 6 78 588 6 79 598 6 54
*p , 0.05 versus controls. Abbreviations as in Table 1.
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panel). There was no change in diastolic [Ca21]i in any group
(data not shown).
Tissue cyclic GMP levels. To determine whether cardiac
cyclic GMP levels were intrinsically depressed in the experi-
mental model of pressure overload, we measured tissue LV
cyclic GMP levels in all groups (Table 3). Cyclic GMP levels
were similar in LV tissues of rats with aortic stenosis and
age-matched control rats. Long-term administration of
L-arginine significantly elevated LV cyclic GMP levels in rats
with aortic stenosis compared with untreated rats with aortic
stenosis. As a positive control of the effects of long-term
L-arginine treatment on NO-mediated signaling, cyclic GMP
content was also assessed in kidneys. Renal cyclic GMP levels
were higher in untreated animals with aortic stenosis com-
pared with untreated control animals. Furthermore, L-arginine
treatment significantly increased renal cyclic GMP content in
control rats as well as in rats with aortic stenosis.
Left ventricular nitric oxide synthase mRNA and protein
levels. Levels of LV cNOS mRNA, which were measured by
RNase protection assay and expressed as densitometric units
normalized to beta-actin, were similar between untreated
control animals and animals with aortic stenosis (0.181 6
0.021 vs 0.152 6 0.017 U, p 5 NS).
Steady-state levels of LV cNOS were determined by West-
ern analysis. On each gel, samples from each group were
normalized to the signal obtained from the control human
endothelial cell protein standard. Left ventricular cNOS pro-
tein levels were similar between untreated control rats and
animals with aortic stenosis (0.811 6 0.084 vs 0.703 6 0.052 U,
p 5 NS). In rats with aortic stenosis, L-arginine treatment
induced a 35% increase in cNOS protein levels compared with
untreated animals (p 5 0.09). In control animals, L-arginine
induced a 25% increase in LV cNOS protein levels (p 5 0.11).
LV inducible NOS protein levels were not detectable in any
group.
Discussion
Previous studies in genetic models of essential hypertension
(16–19) have raised the provocative hypothesis that a funda-
mental defect in pressure overload hypertrophy is deficient
NO-cyclic GMP signaling, and have shown that long-term
L-arginine administration is associated with an increase of
cardiac cyclic GMP levels and regression of cardiac hypertro-
phy (20). However, it is not known whether NO-cyclic GMP
signaling is deficient in other models of pressure overload and
whether long-term L-arginine treatment can modify hypertro-
phic growth and/or myocardial performance in compensatory
experimental mechanical pressure overload hypertrophy.
Thus, the present study investigated the effect of long-term
L-arginine treatment on cardiac hypertrophy and myocardial
function in rats with compensatory pressure overload hyper-
trophy due to ascending aortic stenosis. In contrast with the
genetic models of the spontaneously hypertensive rat, this
Figure 3. Graph showing the contractile response to isopro-
terenol in isolated control (left panel) and hypertrophied
(right panel) myocytes. Abbreviations as in Figure 1.
Figure 4. Graph showing the relation between isopro-
terenol infusion and changes in peak systolic intracel-
lular calcium in control (left panel) and hypertrophied
(right panel) myocytes. Abbreviations as in Figure 1.
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model provides a pure mechanical pressure overload on the
heart in the absence of systemic hypertension (2,23), and
separates potential confounding effects of genetic alterations
in NO-cyclic GMP signaling.
Nitric oxide-cyclic GMP signaling in compensatory hyper-
trophy. Prior studies (1,2,24) have demonstrated that long-
term ACE inhibition promotes regression of pressure overload
hypertrophy. Because long-term ACE inhibition may lead to
an enhanced action of cardiac NO-cyclic GMP pathway via
inhibition of bradykinin degradation (4,5), this has led to
speculation that cardiac NO-cyclic GMP signaling may be
altered in pressure overload hypertrophy.
Our data show that compensatory pressure overload hyper-
trophy is not associated with a deficiency in LV cyclic GMP
production. This finding contrasts with data obtained in a
genetic spontaneously hypertensive rat model (18); however, it
corroborates previous studies (25,26) that reported an increase
rather than deficit in cardiac cyclic GMP content in experi-
mental compensatory pressure overload hypertrophy.
Our data also show that both LV mRNA and LV protein
levels of cNOS are similar between untreated control rats and
rats with aortic stenosis. In contrast, studies in spontaneously
hypertensive rats reported an upregulated cNOS activity in
cardiac endothelial cells (27) as well as in isolated myocytes
(28,29). Although it is unclear what underlies these discrepan-
cies, it is possible that different mechanisms of increased
systolic load may have distinct effects on each component of
the L-arginine/NO signaling cascade, including interplay with
other mediators such as atrial natriuretic peptide, endothelin,
prostaglandins or neuregulins. Taken together, the current
data suggest that the transcriptional and functional response of
the L-arginine/NO pathway to pressure overload is complex
and not predictable purely from an increase in systolic load per
se.
Effects of L-arginine/nitric oxide-cyclic GMP pathway on
cardiac hypertrophy. Several studies have shown a growth
suppressant effect of NO and its donors using in vitro prepa-
rations of vascular smooth muscle cells (14,15) mediated by
cyclic GMP dependent kinases (30). However, it is not yet
known whether NO unambiguously suppresses the growth of
cardiac myocytes in culture or in intact adult hearts. Harding et
al. (31) reported that a high dose of nitroglycerin reduced basal
and phenylephrine-induced protein synthesis in cultured neo-
natal myocytes. It is possible that at nonphysiologic high doses
of NO donors in vitro in the absence of hemoglobin, genera-
tion of peroxynitrate, rather than direct effect of NO, may be
responsible for growth inhibition in cultured cells (32). Mat-
suoka et al. (18) demonstrated that long-term L-arginine
administration attenuated cardiac mass in the genetic sponta-
neously hypertensive rat model. In that study, cardiac cyclic
GMP levels were markedly depressed in the spontaneously
hypertensive rats and L-arginine administration normalized
depressed cyclic GMP production without changes in mean
arterial pressure. Thus, a higher availability of L-arginine as a
substrate for an upregulated NOS (27–29) might be beneficial
in suppressing myocyte growth in spontaneously hypertensive
rats.
In the present study, the dose of L-arginine was sufficient to
achieve the metabolic end point of an increase in renal (33)
and LV cyclic GMP (18). It is notable that although L-arginine
treatment increased LV cyclic GMP in the rats with aortic
stenosis, the extent of LV mass remained unchanged. Thus, in
the presence of persistent severe LVSP overload due to aortic
stenosis, LV cyclic GMP levels are not decreased and further
augmentation of NO-mediated cyclic GMP levels does not
suppress cardiac growth. The different outcome of long-term
L-arginine treatment on hypertrophic growth in the mechanical
pressure overload, in contrast to the genetic models of hyper-
tension such as a spontaneously hypertensive rat, suggests that
L-arginine stimulation of NO-cyclic GMP does not change LV
mass when basal LV cyclic GMP levels are preserved. How-
ever, neither our nor previous studies address the possibility
that L-arginine treatment might have modified in vivo LV
concentric remodeling (wall thickness/chamber diameter ra-
tio), which has not been assessed, without changes in the extent
of LV mass.
Effects of L-arginine/NO pathway on myocardial perfor-
mance in LV hypertrophy. The present study demonstrates for
the first time that long-term stimulation of NO-mediated cyclic
GMP depresses LV contractile function. Because L-arginine
treatment did not alter tail-cuff systolic blood pressure, the
reduction in LVSP generation in vivo in rats with aortic
stenosis can be attributed to a direct negative inotropic effect
on myocardium. This effect is concordant with acute modula-
tion of contractile performance by NO in the absence of
beta-adrenergic stimulation (6–8,34,35) which is attributed
predominantly to a myofilament desensitization (8,21,36,37).
We recently demonstrated that myofilament desenzitization by
NO donors and 8-bromo-cyclic GMP is likely due to altered
Na1-H1 exchange resulting in a reduction of intracellular pH
(21). Of note, unchanged tail-cuff pressure and reduced LV
pump function in the presence of a fixed aortic stenosis in the
L-arginine treated rats with aortic stenosis suggests a reflexive
Table 3. Tissue Cyclic GMP Levels
C C-L-arg LVH LVH-L-arg
LV cyclic GMP (pmol/g dry weight) 27.71 6 4.81 37.22 6 4.86 36.09 6 4.39 56.53 6 7.52*†
Renal cyclic GMP (pmol/g dry weight) 19.83 6 5.45 89.05 6 16.96† 43.31 6 8.94 106.95 6 21.14*†
n 5 5 to 12 per group. *p , 0.05 versus control animals; †p , 0.05 versus untreated animals. Abbreviations as in
Table 1.
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adjustment of systemic resistance to maintain systemic blood
pressure.
In this study, we also observed that long-term L-arginine
treatment caused a blunted beta-adrenergic contractile re-
sponse to isoproterenol in hypertrophied hearts and myocytes.
Several studies have shown the acute depression of the con-
tractile response to beta-adrenergic stimulation by endogenous
NO in cytokine-treated myocytes (9), in isolated papillary
muscles (11) and in human studies (10,12). An attenuated
contractile response to isoproterenol mediated by NO was also
observed in failing myocytes due to pacing-induced heart
failure (13). Our observation that long-term L-arginine treat-
ment depresses the beta-adrenergic inotropic response in
compensatory hypertrophy is novel, and suggests an interven-
tion with the potential to limit pathologic beta-adrenergic
stimulation in the presence of LVH.
The present study suggests that in the presence of beta-
adrenergic stimulation, the reduction of the force generation
by endogenous NO-mediated cyclic GMP signaling is mediated
by a blunted increase in peak systolic calcium in response to
beta-adrenergic stimulation. This idea is supported by prior
studies demonstrating the NO-cyclic GMP mediated suppres-
sion of the inward L-type calcium current in stimulated myo-
cytes (7,38). This effect may also be related to the interplay
between the NO-cyclic GMP pathway and the regulatory
inhibitory G protein, which has been recently described by
Hare et al (39). It should be noted that although beta-
adrenergic receptor density was not measured in our study, the
beta-adrenergic contractile reserve was intact in myocytes from
untreated rats with aortic stenosis at this stage of compensa-
tory hypertrophy. Hence, the impaired response to isoproter-
enol is consistent with elevated levels of LV cyclic GMP in
L-arginine treated animals with LVH. Thus, our study and
previous studies (7,8,21,36,37) support the hypothesis of at
least two complementary mechanisms involved in NO-cyclic
GMP mediated modulation of myocardial contractility. First,
myofilament desensitization appears to underlie the negative
inotropic effects in the absence of beta-adrenergic stimulation,
and second, inhibition of adrenergically stimulated calcium
signaling appears to modulate the inotropic response in the
presence of beta-adrenergic stimulation.
Study limitations. There are several limitations of the
current study. First, we investigated the effects of L-arginine
treatment at the stage of early compensated LVH. Thus, it
remains uncertain whether L-arginine treatment will augment
cyclic GMP signaling at a later stage of decompensated
pressure overload hypertrophy. Second, we did not directly
measure steady-state or stimulated endogenous cardiac NO
production. Accordingly, it cannot be ruled out that some of
the effects of L-arginine treatment on cardiac cyclic GMP are
not related to NO. Third, it is unclear why L-arginine caused a
greater increase in LV cyclic GMP levels in animals with aortic
stenosis than in control animals. We speculate that this could
be related to differences in L-arginine transport in control and
hypertrophied hearts (40).
Study implications. In the present study, L-arginine treat-
ment elevated LV levels of cyclic GMP in rats with aortic
stenosis. The augmentation of cyclic GMP signaling failed to
change LV mass in these rats. Nonetheless, long-term
L-arginine treatment caused a mild depression of in vivo LV
contractile function in rats with aortic stenosis and blunted the
beta-adrenergic contractile response to isoproterenol in intact
hypertrophied hearts and isolated myocytes. Beneficial or
adverse long-term effects of the stimulation of NO-cyclic GMP
signaling and interference with beta-adrenergic signaling on
myocardial function, myocardial energetics, and the later
transition to cardiac failure in the presence of mechanical
pressure overload are unknown and require further investiga-
tion.
We greatly appreciate the thoughtful comments and suggestions of Drs. Thomas
W. Smith, Ralph A. Kelly, Cardiovascular Division, Brigham and Women’s
Hospital, Boston, Massachusetts, and Thomas H. Hintze, Department of Phys-
iology, New York Medical College, Valhalla, New York, to our study.
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